False-positive SARS-CoV-2 with HRV-A infection

Shogo Otake,1 Sonoko Miyamoto,2 Ai Mori,2 Tomotada Iwamoto2 and Masashi Kasai1

1Division of Infectious Disease, Department of Pediatrics, Hyogo Prefectural Kobe Children’s Hospital, 2Department of Infectious Diseases, Kobe Institute of Health, Kobe, Japan

Key words coronavirus disease 2019, enterovirus, human rhinovirus, rapid antigen test, severe acute respiratory coronavirus 2.

Since the outbreak of coronavirus disease-2019 (COVID-19) in December 2019, more than 40 million people have been infected and more than 1 million have died. In Japan, approximately 80,000 people have been infected.1 The gold standard for testing is the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA through reverse transcriptase polymerase chain reaction (RT-PCR).2 However, only a few facilities perform RT-PCR testing, while others alternatively perform the antigen test. Espline SARS-CoV-2 (Fujirebio, Tokyo, Japan) is a SARS-CoV-2 antigen detection test in which the nasopharyngeal swab is obtained and tested by immunochromatography based on enzyme immune response.2 According to the clinical guidelines in Japan, patients with positive rapid antigen results are declared COVID-19 positive.2 The rapid antigen test was introduced for the benefit of obtaining results easily and quickly. We performed multiplex PCR using a FilmArray Respiratory Panel 2.1 (FilmArray; Bio Mérieux, Marcy-l’Etoile, France) for the patients who tested positive through the rapid antigen test. FilmArray Respiratory Panel 2 demonstrated a positive agreement of 91.7% and a negative agreement of 93.8% based on FilmArray Respiratory Panel or two PCR assays targeting IS1001 for Bordetella parapertussis, followed by bidirectional sequencing.3 FilmArray can detect 21 microorganisms simultaneously, including the SARS-CoV-2. Here we report three cases of human rhinovirus A (HRV-A) infection where the patients presented with false-positive results for SARS-CoV-2 on the rapid antigen test.

Table 1 shows the three cases. Case 1 was a 3-year-old boy with trisomy 13, who was admitted to the hospital because of fever, cough, and hypoxemia. Case 2 was a 2-year-old girl with central hypoventilation syndrome, who presented with fever and rhinorrhea, and convulsions due to hyponatremia. Case 3 was a 17-year-old girl admitted due to hypoxemia, with a history of surgery for congenital heart disease. None of these patients came in contact with COVID-19 patients. We determined their SARS-CoV-2 on rapid antigen test results to be positive for SARS-CoV-2 because both the reference lines and test lines appeared within 30 min after testing at admission. However, FilmArray detected HRV/enterovirus and not
SARS-CoV-2. We extracted viral RNA from nasopharyngeal swabs and performed RT-PCR and DNA sequencing to identify the type of enterovirus. In all three cases, we detected HRV-A, not SARS-CoV-2.

From our cases, we have two clinically important suggestions. First, since false positives have a large impact, patients should be selected not only for symptoms but also for a history of close contact with COVID-19 patients, especially in children. A systematic review of 7,780 pediatric COVID-19 patients reported that 19.3% were asymptomatic. Even in symptomatic patients, there were many nonspecific symptoms such as fever (59.1%) and cough (55.9%). In addition, 5.6% of the cases were co-infected with other viral infections. In this systematic review, 75.6% of patients were exposed to the infection from the family. A history of contact with COVID-19 patients affects the pretest probability more than clinical symptoms only when the risk of social exposure is low. False positives have a large impact on the patient in terms of physical, mental, and financial burden because persons diagnosed with COVID-19 in Japan must be hospitalized.

Second, we should reconfirm through the RT-PCR test when Espline SARS-CoV-2 is positive at the current epidemic level in Japan. In Japan, even if the rapid antigen test result for symptomatic patients is positive, the causative organism could be more common viruses, including HRV, and the rapid test result could be false positive. No false-positive results for Espline SARS-CoV-2 have been reported owing to cross-reactivity with HRV. In other countries, cross-reactivity between SARS-CoV-2 antigens and other infectious diseases such as other coronaviruses, influenza virus, and *Mycoplasma pneumoniae* has been reported. The possible reasons for false-positive results could be low prevalence of the disease in Japan and influence of the test kit. The lower the prevalence is the higher the false positive rate of the test becomes. However, Kobe city has a large number of COVID-19 patients in Japan. Additionally, since the three patients were tested with a kit of the same production lot number (K4B-039), false-positive results may be possible. However, when re-examined using a kit with a different production lot number (K4B-019), the result was again positive in Case 3.

Thus, the indications for rapid antigen tests should be reconsidered, especially in children without any history of the contact with COVID-19 patients. Reconfirmation is warranted through the RT-PCR test when Espline SARS-CoV-2 is positive at the current epidemic level in Japan.

### Acknowledgments

We are grateful to Akihiro Ijichi (Director, Kobe City Health and Welfare Bureau Health Center, Hyogo, Japan), Akemi Ozaki (Manager, Preventive Hygiene Division, Kobe City Health and Welfare Bureau Health Center, Hyogo, Japan), and Yui Nakagawa (Radiation microbiology technician, Department of Clinical Laboratory, Hyogo Prefectural Kobe Children’s Hospital, Hyogo, Japan) for their cooperation with the PCR tests to detect the types of HRV/enterovirus.

### Disclosure

The authors declare no conflicts of interest.

### Author contributions

S.O. wrote the manuscript; A.M. and M.K. provided conceptual advice; S.M., A.M., and T.I. provided technical support, and collected and analyzed data. All authors have read and approved the final manuscript.

### Informed consent

We obtained informed consent from the patients’ parents to publish this case report.

---

**Table 1 Three cases with false-positive results in SARS-CoV-2 rapid antigen tests**

| Diagnosis | Case 1; 3-year-old boy | Case 2; 2-year-old girl | Case 3; 17-year-old girl |
|-----------|------------------------|-------------------------|-------------------------|
| Symptoms  | Acute bronchiolitis    | Hyponatremia            | Acute pneumoniae        |
|           | Fever, cough, hypoxemia| Fever, nasal discharge, convulsion central hypoventilation syndrome, central diabetes insipidus, post tracheostomy | Sore throat, cough, hypoxemia Congenital cardiac disease (corrected transposition of great arteries, atrioventricular septal defect) |
| Underlying diseases | Trisomy 13, very low birthweight infant, laryngomalacia, post tracheostomy | Trisomy 13, very low birthweight infant, laryngomalacia, post tracheostomy | Trisomy 13, very low birthweight infant, laryngomalacia, post tracheostomy |
| A history of close contact with COVID-19 patients | None | None | None |
| Inspection day | Espline SARS-CoV-2 Day 6 | FilmArray Respiratory Panel 2.1 Day 7 | FilmArray Respiratory Panel 2.1 Day 7 |
| Production lot number of Espline SARS-CoV-2 | K4B-039 | K4B-039 | K4B-039, K4B-019, K4B-039 |
| Results of FilmArray Respiratory Panel 2.1 | Human rhinovirus/enterovirus | Human rhinovirus/enterovirus | Human rhinovirus/enterovirus |
| Type of enterovirus | Human rhinovirus A85 | Human rhinovirus A82 | Human rhinovirus A11 |
A case of “asymmetrical” Graves’ disease with lateral radioisotope uptake

Yutaka Konda,1 Kanshi Minamitani,2 Tomozumi Takatani,1 Shoko Kure3 and Iwao Sugitani4

1Department of Pediatrics, Chiba University Graduate School of Medicine, 2Department of Pediatrics, Teikyo University Chiba Medical Center, Chiba, 3Department of Diagnostic Pathology, Nippon Medical School, Musashi-Kosugi Hospital, Kanagawa, 4Department of Endocrine Surgery, Nippon Medical School, Tokyo, Japan

Key words goiter, Graves’ Disease, hyperthyroidism, pediatric, scintigraphy.

An 11-year-old female presented with thyrotoxicosis and no remarkable medical history, although her mother had Hashimoto thyroiditis. She had experienced dizziness and palpitations for 1 year. Her height and weight were 148 cm (−0.4 SD) and 38 kg (body mass index SDS −0.16 SD), respectively, and reported no height spurt or weight loss. She displayed tachycardia and no tremor nor proptosis. Her goiter was elastic, soft, almost equally swollen on both sides by visual inspection and was grade 1 by the World Health Organization classification. No palpable thyroid nodules were noted.

Figure 1a displays the clinical course chart. Her initial thyroid-stimulating hormone and free thyroxine levels were <0.1 µU/mL and 3.3 ng/dL, respectively, and her thyroglobulin antibody, thyroid peroxidase antibody, thyrotropin receptor antibody (TRAb), and thyroid-stimulating antibody (TSAb) levels were 600 U/mL, 258 U/mL, <1.5 U/L, and 132%, respectively. The thyroid ultrasound displayed a right lobe of 5.9 mL and a left lobe of 7.7 mL (standard <6.1 mL and <4.9 mL, respectively) (Fig. 1b). Both lobes displayed a coarse texture and increased echogenicity, and there were no findings of increased vascularity or thyroid nodule. 123I thyroid scintigraphy was performed, because of the low TRAb levels. Increased iodine uptake was observed, predominantly in the left lobe in color scintigraphy, but increased uptake in the right lobe was also noted in a monochrome image. The total iodine uptake was 75%. We further recalculated the iodine uptake in both lobes separately and identified uptakes of 56.6% in the left lobe and 20.7% in the right lobe (Fig. 1c). From these results, we diagnosed her with Graves’ disease and initiated methimazole (MMI). We added potassium iodide (KI) because the effect of treatment with MMI alone was insufficient. However, she felt leg pain and her the creatinine kinase level was 88 IU/L. Thus, we stopped MMI and the leg pain improved. With KI therapy, the hyperthyroidism was almost controlled. In general, juvenile Graves’ disease has a high recurrence rate. Furthermore, MMI cannot be used for any future recurrence in this patient because of its side effects. Therefore, total thyroidectomy was performed 4 months after the first medical examination. Medium-sized follicles and collagen fibers were distributed throughout the pathological specimen and no nodules were present. Lymphoplasmacytic infiltration with germinal centers was also observed around the remaining follicles that matched lymphoplasmacytic thyroiditis (Fig. 1d). These findings were found in both lobes equally. Finally, we concluded that she had “asymmetrical” Graves’ disease. She is currently taking levothyroxine and keep euthyroid. Informed consent was obtained from her parents for publication of this report.

This case did not present as silent thyroiditis because of her long clinical course and increased iodine uptake. Autonomously functioning thyroid nodule (AFTN), Marine-Lenhart

References

1 World Health Organization. Coronavirus disease (COVID-19) pandemic. who.int [homepage on the internet] Genève: World Health Organization. [Cited 2020 Oct 21]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2 Ministry of Health, Labor and Welfare. Clinical Management of Patients with COVID-19. A guide for front-line healthcare workers Version 3. mhlw.go.jp [homepage on the internet]. Tokyo: Ministry of Health, Labor and Welfare. [Cited 2020 Oct 5]. Available from: https://www.mhlw.go.jp/content/000668291.pdf
3 Leber AL, Everhart K, Daly JA et al. Multicenter evaluation of BioFire FilmArray respiratory panel 2 for detection of viruses and bacteria in nasopharyngeal swab samples. J. Clin. Microbiol. 2018; 56(6): 1–11.
4 Hoang A, Chorath K, Moreira A et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine 2020; 24: 100433.
5 Deeks JJ, Dinnes J, Takwoingi Y et al. Antibody tests for identification of current and past infection with SARS-CoV-2 (Review). Cochrane Database Syst. Rev. 2020; 2(6): 1–306.

A case of asymmetrical Graves’ disease 1137